Abstract library

360 results for "advanced NETs".
#2954 Aggressive Resection - A Treatment Option in Patients with Advanced Neuroendocrine Tumors
Introduction: Different treatment modalities have been considered for patients with malignant advanced neuroendocrine tumors(NETs) of the pancreas and duodenum.Aggressive surgery remains a controversial yet an efficacious antitumor therapy.
Conference: 17th Annual ENETS Conference (2020)
Category: Surgical treatment and Ablative Therapies
Presenting Author: Doctor Azka Athar
Authors: Athar A
#137 Extensive ""multitasking"" surgery for advanced neuroendocrine tumors is safe and effective
Introduction: Management of advanced NETs is controversial, related to degree of intervention; the pendulum is swinging towards a more aggressive interventional approach. Our Center's philosophy is to offer a systematic, planned multimodality treatment for patients with advanced NETs.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: MD MICHAIL K Shafir
#1308 Systemic Treaments and Prognostic Factors in Chinese Patients with Progressive Advanced Well-differentiated Pancreatic Neuroendocrine Tumors
Introduction: Patients with well-differentiated pancreatic neuroendocrine tumors (pNETs) often present with metastatic disease at the time of diagnosis when curative surgery is not feasible. A variety of systemic therapeutic options exist, but the best strategy is still unknown.
Conference: 13th Annual ENETS conference (2016)
Category: Medical treatment - Others
Presenting Author: Yuejuan Cheng
Authors: Cheng Y, Gao H, Bai C M, Ying H, ...
#706 Is There a Therapeutic Impact of Segmental Portal Hypertension on Advanced Pancreatic Neuroendocrine Tumors?
Introduction: Well-differenciated locally advanced Pancreatic Neuroendocrine Tumors (PNET) lead to significant local complications due to segmental portal hypertension (SPH).
Conference: 10th Annual ENETS Conference (2013)
Category: Surgical treatment
Presenting Author: Dr Frédéric Dumont
#902 Chemotherapy for Advanced Neuroendocrine Tumors (NETs): Patient Selection Should be Independent of Primary Tumor Site
Introduction: Chemotherapy (CT) is used to treat patients (pts) with advanced poorly-differentiated (Pd); or well-differentiated (Wd) NETs with high-tumor burden (usually of pancreatic (pNET) origin).
Conference: 11th Annual ENETS Conference (2014)
Category: Medical treatment - Chemotherapy
Presenting Author: Dr Angela Lamarca
#2240 CT-Guided HDR Brachyterapy in Patients with Advanced Non-Resectable and Progressive NEN with Liver Bulky Disease. Pilot Study
Introduction: CT-Guided HDR Brachyterapy is a new method used for liver metastases treatment.
Conference: 15th Annual ENETS conference (2018)
Category: Imaging and Interventions (radiology, endoscopy)
Presenting Author: Dariusz Kieszko
#1750 Sunitinib as First Line Therapy in Patients with Advanced Pancreatic Neuroendocrine Tumors: Experience of a Single Algerian Center
Introduction: Sunitinib is indicated in the treatment of patients with advanced progressive pancreatic neuroendocrine tumors (pNETs).Its experience as first line therapy is limited.
Conference: 14th Annual ENETS conference (2017)
Category: Medical treatment - Targeted therapies
Presenting Author: doctor Belabdi Djihed
Authors: Djihed B, Alyda M, Mohammed O, ...
#127 Sunitinib for the treatment of advanced, progressive pancreatic neuroendocrine tumors
Introduction: Sunitinib is an oral, multitargeted tyrosine kinase inhibitor approved for use in advanced renal cell carcinoma and imatinib-resistant/intolerant gastrointestinal stromal tumors. Investigations of sunitinib in the RIP1-Tag2 mouse model and in phase I/II clinical trials provide evidence of antitumor activity against pancreatic neuroendocrine tumors (NET).
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Prof Eric Raymond
#233 Afinitor UK Particular Patient Supplies for Advanced Neuroendocrine Tumors (NETs)
Introduction: The PI3/Akt/mTOR pathway is activated by IGF-1 in NETs. mTOR regulates signalling downstream of IGF-1R1: Afinitor and Sandostatin may synergistically arrest growth and secretory activity in NETs.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Mr Jonathan S Chambers
Authors: Chambers J, ...
#257 Doxorubicin, Etoposide and Cisplatin as first-line Treatment in Advanced Adrenocortical Carcinoma
Introduction: Adrenocortical carcinoma (ACC) is a rare cancer with poor prognosis in advanced setting due to its low chemosensibility. Mitotane and cisplatin-based regimens are the most frequently used treatments.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: MD Paula Jiménez Fonseca
Close
Notice

Dear conference participant,

Thank you for participating in the ENETS Virtual Conference 2020!

You now have the opportunity to view the webcasts, abstracts and e-posters via My ENETS. Don't miss out any of the exciting talks and take your time to view the clinical and basic science abstract sessions.

If you require a certificate of attendance, please log into My ENETS and select “Annual Conferences” from the side menu, then click on “My registrations” and select your registration for 2020. Please choose "Certificate o.A." to receive your certificate of attendance.

A note on CME accreditation:

ENETS has been liaising with UEMS regarding CME accreditation for the virtual conference. At present, we do not have a definitive answer. We will keep you updated.

 

Wishing you all the best,

The entire ENETS team